Keele Professor presents cardiology research at global meeting in Paris


Share |
heart
Posted on 16 May 2017

Mamas Mamas, Professor of Cardiology at Keele University and Consultant Cardiologist at the University Hospitals of North Midlands Trust (UHNM), is set to present the findings of a worldwide study at an international meeting in Paris this month.

Professor Mamas will present findings from the ‘e-ULTIMASTER’ trial to the EuroPCR, an annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI), which takes place this week and sees 12,000 delegates in attendance from around the world.

UHNM has been named the highest-recruiting site in the UK for the e-ULTIMASTER trial which looks at patients who have received treatment with the Ultimaster coronary stent. A total of 292 patients have been recruited to the trial at UHNM in just six months, a massive 730 per cent of the original recruitment target of just 40 patients.

Professor Mamas said: “Our success in this trial shows that cardiology research at UHNM is world-class. Data from the e-ULTIMASTER trial will facilitate research that will improve patient care and clinical outcomes.”

Mr Oliver Payne, Clinical Manager at Terumo, the sponsor organisation for the trial, said: “The recruitment to this study remains unprecedented in the UK for Terumo. The study now aims to recruit over 34,000 patients worldwide and the UHNM contribution towards this target has been huge.

“The efficiency and drive of the UHNM research team makes working with this department a pleasure and this is why they have such a high overall standing for recruitment for this study.”

Dr Darren Clement, R&D Manager at UHNM, said: “It is great to once again see UHNM at the forefront of delivering high-quality research for the benefit of our patients. The team here at UHNM has surpassed its original recruitment target and has demonstrated that great team work, together with a focus on doing the best for our patients, really pays dividends. This is a truly great performance and deserves this international recognition.”


back